Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose interferon-alpha plus celecoxib after radiotherapy for hepatocellular carcinoma
ChiCTR-TRC-10000900Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of interferon alfa and celecoxib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Disease-free survival. Started Sep 2010; status: recruiting.
02
Drugs
interferon alfacelecoxib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-10000900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10000900.